Cargando…

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy

PURPOSE: The highest rates of gastric cancer occur in Eastern Asia. Fluoropyrimidine-based therapy is used initially in unresectable and metastatic disease, but no single standard of care exists following disease progression. Ixabepilone, an epothilone B analog, is a non-taxane microtubule-stabilizi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yeul Hong, Muro, Kei, Yasui, Hirofumi, Chen, Jen-Shi, Ryu, Min-Hee, Park, Se-Hoon, Chu, Kent-Man, Choo, Su-Pin, Sanchez, Teresa, DelaCruz, Christine, Mukhopadhyay, Pralay, Lainas, Ioannis, Li, Chung-Pin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456918/ https://www.ncbi.nlm.nih.gov/pubmed/22886073 http://dx.doi.org/10.1007/s00280-012-1943-6

Ejemplares similares

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
por: Vahdat, Linda T., et al.
Publicado: (2012)

Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
por: Rak Tkaczuk, Katherine H.
Publicado: (2011)

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010)

Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009)

Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
por: Ibrahim, Nuhad K.
Publicado: (2021)

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Ixabepilone development across the breast cancer continuum: a paradigm shift
por: Ibrahim, Nuhad K
Publicado: (2010)

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients
por: Ebenezer, Gigi J, et al.
Publicado: (2014)

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
por: Cobham, Marta Vallee, et al.
Publicado: (2009)

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
por: Tanei, Tomonori, et al.
Publicado: (2016)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature
por: Mitani, Seiichiro, et al.
Publicado: (2017)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
por: Ott, Patrick A., et al.
Publicado: (2010)

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells
por: Tam, Stanton, et al.
Publicado: (2022)

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer
por: Ho, Joanne, et al.
Publicado: (2009)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells
por: YAO, YONGSHAN, et al.
Publicado: (2014)

Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
por: Iwasa, Satoru, et al.
Publicado: (2023)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tian, Wei, et al.
Publicado: (2023)

Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_kp68mnbleeetikn46iqqm91ko2